Efficacy of the carbocyclic 2'-deoxyguanosine nucleoside BMS-200475 in the woodchuck model of hepatitis B virus infection.
about
The Discovery and Development of a Potent Antiviral Drug, Entecavir, for the Treatment of Chronic Hepatitis BDirect acting antivirals for the treatment of chronic viral hepatitisAntiviral L-nucleosides specific for hepatitis B virus infectionThe polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistanceAntiviral activity of beta-L-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine in woodchucks chronically infected with woodchuck hepatitis virusPotent efficacy of entecavir (BMS-200475) in a duck model of hepatitis B virus replication.Effect of antiviral treatment with entecavir on age- and dose-related outcomes of duck hepatitis B virus infection.Low dynamic state of viral competition in a chronic avian hepadnavirus infection.The woodchuck as an animal model for pathogenesis and therapy of chronic hepatitis B virus infectionKinetics of hepadnavirus loss from the liver during inhibition of viral DNA synthesis.Emergence of drug-resistant populations of woodchuck hepatitis virus in woodchucks treated with the antiviral nucleoside lamivudineCharacterization of the antiviral effect of 2',3'-dideoxy-2', 3'-didehydro-beta-L-5-fluorocytidine in the duck hepatitis B virus infection model.Antiviral activities of oral 1-O-hexadecylpropanediol-3-phosphoacyclovir and acyclovir in woodchucks with chronic woodchuck hepatitis virus infectionMutations of the woodchuck hepatitis virus polymerase gene that confer resistance to lamivudine and 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil.Entecavir therapy combined with DNA vaccination for persistent duck hepatitis B virus infection.Hepadnavirus Genome Replication and Persistence.Formation of hepatitis B virus covalently closed circular DNA: removal of genome-linked proteinAntiviral effect of orally administered (-)-beta-D-2-aminopurine dioxolane in woodchucks with chronic woodchuck hepatitis virus infection.Hepatocyte turnover during resolution of a transient hepadnaviral infection.Antiviral Efficacy and Host Immune Response Induction during Sequential Treatment with SB 9200 Followed by Entecavir in Woodchucks.The amount of hepatocyte turnover that occurred during resolution of transient hepadnavirus infections was lower when virus replication was inhibited with entecavir.Antiviral activity, dose-response relationship, and safety of entecavir following 24-week oral dosing in nucleoside-naive Japanese adult patients with chronic hepatitis B: a randomized, double-blind, phase II clinical trial.In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir.Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro.Therapeutic vaccination in chronic hepatitis B: preclinical studies in the woodchuck.Profound antiviral effect of oral administration of MIV-210 on chronic hepadnaviral infection in a woodchuck model of hepatitis BZinc finger proteins designed to specifically target duck hepatitis B virus covalently closed circular DNA inhibit viral transcription in tissue culture.Combination of an antiviral drug and immunomodulation against hepadnaviral infection in the woodchuck model.
P2860
Q27007019-DEC9791C-3148-46B3-A76F-14E18ACC82DFQ27022216-D1E67641-0D77-4709-9F08-96EB258523ACQ28345251-37706FFE-93D8-47BA-81AA-19C5E1FBCD67Q28350136-945E0914-C60F-4D3A-B99D-882D9CFA4BC3Q28360714-F484BFB0-14A8-47AD-ADDE-905DA6C954E4Q28366818-64FFE147-F73D-4AA1-BD1A-09806F8D743EQ33755065-BC0A4206-9148-4071-969C-616B4865E165Q33787127-2DD60712-DFE3-454A-BECB-13B111D9F314Q33787525-25B44066-2F28-4EE3-BB94-39A4C5EB1313Q33834863-AABD110F-45E0-45F3-8111-022B452F1A13Q33977402-54627F03-FF64-45CA-AF08-3A991CC3D653Q33978482-4A258CE7-B498-4CEE-84C3-82E26C357132Q33980098-CB10D1F8-7112-497C-B75A-B732727F825DQ34330228-EA5F4797-02DE-4BCC-8286-648AF9F84C8DQ35166065-2336A621-CF2A-430B-AE91-DAA4DB786A0DQ35795545-D4719261-B9F0-4005-AAE6-75DF162641C4Q35857166-9571C886-182F-419F-B40D-CA656AD0439AQ36094811-1C22A7DB-2D4A-4F7B-9D25-F92D7A58D185Q36161444-19C6F0FB-CF70-468B-AA89-58C635965B89Q36240367-72B253C6-D9DE-40D3-91F9-C297090CEBE0Q37099820-BB3584CE-8AC1-4884-8B8A-42DFDE29DEBFQ37356804-56E5A24E-6DB5-4832-BB93-BEB9731ED34AQ39559675-C4BBA149-A32C-4FC9-8A5E-1A6BBAE76166Q39652624-F88E1813-08A6-403A-9933-59942D0D0048Q41218508-24D0DA69-BE56-492D-845D-6976C1D74E4FQ42004056-A8A1F3C0-589E-4EFB-8D5C-5D682751ED5DQ42041585-A389045C-506F-40CC-9868-64B3166FF094Q43064406-E33CCF74-2D64-4AC3-90E8-F26425B1B7E8
P2860
Efficacy of the carbocyclic 2'-deoxyguanosine nucleoside BMS-200475 in the woodchuck model of hepatitis B virus infection.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
1998年论文
@zh
1998年论文
@zh-cn
name
Efficacy of the carbocyclic 2' ...... f hepatitis B virus infection.
@en
Efficacy of the carbocyclic 2' ...... f hepatitis B virus infection.
@nl
type
label
Efficacy of the carbocyclic 2' ...... f hepatitis B virus infection.
@en
Efficacy of the carbocyclic 2' ...... f hepatitis B virus infection.
@nl
prefLabel
Efficacy of the carbocyclic 2' ...... f hepatitis B virus infection.
@en
Efficacy of the carbocyclic 2' ...... f hepatitis B virus infection.
@nl
P2093
P2860
P1476
Efficacy of the carbocyclic 2' ...... f hepatitis B virus infection.
@en
P2093
D N Standring
E V Genovesi
R J Colonno
P2860
P304
P407
P577
1998-12-01T00:00:00Z